

(54) Title
4-[5-(Pyridin-4-yl)-1H-1,2,4-Triazol-3-yl]Pyridine-2-Carbonitrile Crystalline Polymorph and Production Method Therefor

(51) International Patent Classification(s)
C07D 401/14 (2006.01) **A61P 19/06** (2006.01)
A61K 31/444 (2006.01) **A61P 43/00** (2006.01)

(21) Application No: **2013293973** (22) Date of Filing: **2013.07.24**

(87) WIPO No: **WO14/017515**

(30) Priority Data

(31) Number	(32) Date	(33) Country
2012-177539	2012.07.25	JP

(43) Publication Date: **2014.01.30**

(44) Accepted Journal Date: **2017.04.06**

(71) Applicant(s)
Fujiyakuhin Co., Ltd.

(72) Inventor(s)
Iwabuchi, Yoshiyuki;Miyata, Sachiko;Sato, Takahiro;Uda, Junichiro;Kandou, Takamitsu;Inoue, Tadashi;Nakano, Hiroyuki

(74) Agent / Attorney
Griffith Hack, GPO Box 1285, Melbourne, VIC, 3001, AU

(56) Related Art
EP 1650204 A1
EP 1471065 A1
CAIRA M R, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局

(43) 国際公開日
2014年1月30日(30.01.2014)



(10) 国際公開番号
WO 2014/017515 A1

- (51) 国際特許分類:
C07D 401/14 (2006.01) A61P 19/06 (2006.01)
A61K 31/444 (2006.01) A61P 43/00 (2006.01)
- (21) 国際出願番号: PCT/JP2013/070004
- (22) 国際出願日: 2013年7月24日(24.07.2013)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ:
特願 2012-177539 2012年7月25日(25.07.2012) JP
- (71) 出願人: 株式会社富士薬品(FUJIYAKUHIN CO., LTD.) [JP/JP]; 〒3309508 埼玉県さいたま市大宮区桜木町4-383 Saitama (JP).
- (72) 発明者: 岩淵 剛行(IWABUCHI, Yoshiyuki); 〒3310047 埼玉県さいたま市西区指扇3936-2 株式会社富士薬品 第一研究所内 Saitama (JP). 宮田 幸帆(MIYATA, Sachiko); 〒3310047 埼玉県さいたま市西区指扇3936-2 株式会社富士薬品 第一研究所内 Saitama (JP). 佐藤 隆弘(SATO, Takahiro); 〒3310047 埼玉県さいたま市西区指扇3936-2 株式会社富士薬品 第一研究所内 Saitama (JP). 雨田 淳一郎(UDA,

Junichiro); 〒3310047 埼玉県さいたま市西区指扇3936-2 株式会社富士薬品 第一研究所内 Saitama (JP). 神藤 高光(KANDOU, Takamitsu); 〒3310068 埼玉県さいたま市西区飯田新田636-1 株式会社富士薬品 第二研究所内 Saitama (JP). 井上 正(INOUE, Tadashi); 〒3310068 埼玉県さいたま市西区飯田新田636-1 株式会社富士薬品 第二研究所内 Saitama (JP). 中野 浩行(NAKANO, Hiroyuki); 〒3309508 埼玉県さいたま市大宮区桜木町4-383 株式会社富士薬品内 Saitama (JP).


- (74) 代理人: 特許業務法人アルガ特許事務所(THE PATENT CORPORATE BODY ARUGA PATENT OFFICE); 〒1030013 東京都中央区日本橋人形町1丁目3番8号 沢の鶴人形町ビル Tokyo (JP).
- (81) 指定国 (表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL,

[続葉有]

(54) Title: 4-[5-(PYRIDINE-4-YL)-1H-1,2,4-TRIAZOLE-3-YL]PYRIDINE-2-CARBONITRILE CRYSTALLINE POLYMORPH AND PRODUCTION METHOD THEREFOR

(54) 発明の名称: 4-[5-(ピリジン-4-イル)-1H-1, 2, 4-トリアゾール-3-イル]ピリジン-2-カルボニトリルの結晶多形およびその製造方法

[図8]



AA Dissolution amount (µg/mL)
BB Crystalline form
CC Hydrate

(57) Abstract: Provided are a 4-[5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl]pyridine-2-carbonitrile crystalline polymorph, which is useful as a pharmaceutical product, and a production method therefor. The present invention relates to a 4-[5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl]pyridine-2-carbonitrile crystalline polymorph, and three different crystalline forms are obtained by purification via a salt, storage under humidified conditions or recrystallization.

(57) 要約: 医薬品として有用な4-[5-(ピリジン-4-イル)-1H-1, 2, 4-トリアゾール-3-イル]ピリジン-2-カルボニトリルの結晶多形および製造方法の提供。4-[5-(ピリジン-4-イル)-1H-1, 2, 4-トリアゾール-3-イル]ピリジン-2-カルボニトリルの結晶多形に関し、塩を経由することによる精製、再結晶又は加湿条件下の保存により、異なる3種の結晶形を得る。

WO 2014/017515 A1



SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, ZA, ZM, ZW.

FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK,
MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM,
ML, MR, NE, SN, TD, TG).

(84) 指定国 (表示のない限り、全ての種類の広域保
護が可能): ARIPO (BW, GH, GM, KE, LR, LS, MW,
MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラ
シア (AM, AZ, BY, KG, KZ, RU, TJ, TM), ヨーロッ
パ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

添付公開書類:

— 国際調査報告 (条約第 21 条(3))

Description

4-[5-(Pyridin-4-yl)-1H-1,2,4-Triazol-3-yl]Pyridine-2-Carbonitrile Crystalline Polymorph and Production Method Therefor

Technical Field

[0001]


The present invention relates to a crystalline polymorph of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile and to a production method therefor.

Background Art

[0002]

Compound (1), 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, is known to serve as a drug which has a xanthine oxidase inhibitory action and which can lower serum uric acid level (Patent Document 1).

[0003]



[0004]

There have been reported several methods for producing the above compound (1). In one production method, methyl isonicotinate N-oxide is subjected to Reissert Henze reaction,

to thereby form methyl 2-cyanoisonicotinate, which is transformed into a hydrazide, and the hydrazide is condensed with 4-cyanopyridine (Patent Document 1, Example 12). In another production method, isonicotinic acid N-oxide is transformed into a hydrazide, into which a cyano group is incorporated through Reissert Henze reaction, and the product is condensed with 4-cyanopyridine (Patent Document 1, Example 39). In an alternative production method, 4-cyanopyridine-N-oxide (starting material) is condensed with isonicotinic acid hydrazide, to thereby form a triazole ring, which is then protected (Patent Document 2) or non-protected (Patent Document 3), and a cyano group is incorporated into the product through Reissert Henze reaction, to thereby yield compound (1).

[0005]

Meanwhile, crystalline polymorphism means such a condition that a compound formed of a unique molecule having a unique chemical composition exists in two or more crystal forms having different molecular arrangements. When a pharmaceutical compound is such a compound, pharmacological activity, solubility, bioavailability, stability, and the like of the compound are known to vary depending on the physicochemical properties intrinsic to the polymorph. Thus, when the useful pharmaceutical compound includes crystalline polymorphs, a compound of a crystal form which provides high utility is preferably produced.

Citation List

Patent Document

[0006]

Patent Document 1: WO2003/064410

Patent Document 2: WO2005/009991

Patent Document 3: JP-A-2005-41802

Summary of the Invention

Problems to be Solved by the Invention

[0007]

However, the aforementioned Patent Documents disclose production methods for 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, but do not disclose crystalline polymorphism of the compound. The disclosed production methods are provided for the purpose of enhancement in yield and chemical purity. That is, these patent documents describe no crystallographic aspect of the compound.

[0008]

Thus, it would be advantageous to provide a pharmaceutically useful novel crystal form of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, whose crystalline polymorphism has not yet been elucidated. It would also be advantageous to provide a production method therefor.

Means for Solving the problems

[0009]

The present inventors have conducted extensive studies in order to solve the aforementioned problems, and have found that treating free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with an acid, to form a

corresponding salt, treating the salt with a base, and neutralizing the base-treated product with an acid can yield type I crystals thereof. The inventors have also found that recrystallizing free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile from an organic solvent can yield type II crystals thereof. The inventors have also found that storing free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile under humidified conditions can yield a hydrate thereof.

[0010]

Accordingly, the present invention provides the following [1] to [9].

[1] Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile exhibiting characteristic peaks in powder X-ray diffractometry at diffraction angles (2θ) of about 10.1° , 16.0° , 20.4° , 25.7° , and 26.7° .

[2] Type II crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile exhibiting characteristic peaks in powder X-ray diffractometry at diffraction angles (2θ) of about 9.9° , 16.3° , 18.2° , and 22.4° .

[3] A hydrate of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile exhibiting characteristic peaks in powder X-ray diffractometry at diffraction angles (2θ) of about 8.1° , 14.9° , 16.4° , 25.3° , 26.9° , and 27.6° .

[4] A method for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, the method comprising treating an acid salt of 4-[5-(pyridin-4-

yl)-1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile with a base and subsequently neutralizing the treated product with an acid.

[5] A method for producing type II crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile, the method comprising recrystallizing 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile from an organic solvent.

[6] A method for producing a hydrate of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile, the method comprising storing 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile under humidified conditions.

[7] A pharmaceutical composition comprising the type I crystals as recited in [1] above, and a pharmaceutically acceptable carrier.

[8] A pharmaceutical composition comprising the type II crystals as recited in [2] above, and a pharmaceutically acceptable carrier.

[9] A pharmaceutical composition comprising the hydrate as recited in [3] above, and a pharmaceutically acceptable carrier.

[0010a]

The present invention as claimed herein is described in the following items 1 to 3:

1. Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile exhibiting characteristic peaks in powder X-ray diffractometry at diffraction angles 2θ of about 10.1° , 16.0° , 20.4° , 25.7° , and 26.7° .

2. A method for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile as recited in item 1, the method comprising treating an acid salt of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with a base and subsequently neutralizing the treated product with an acid.

3. A pharmaceutical composition comprising the type I crystals as recited in item 1, and a pharmaceutically acceptable carrier.

Effects of the Invention

[0011]

The present invention enables provision of type I crystals, type II crystals, and a hydrate of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, which are useful pharmaceuticals.

[0012]

The present invention enables provision of methods for separately producing type I crystals, type II crystals, and a hydrate of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile.

[0013]

In particular, the type I crystals thereof are more useful than the other crystal forms, from the viewpoints of industrial superiority, solubility, and crystal form stability.

Brief Description of the Drawings

[0014]

[Fig. 1] An powder X-ray diffraction pattern of type I crystals.

[Fig. 2] An powder X-ray diffraction pattern of type II crystals.

[Fig. 3] An powder X-ray diffraction pattern of the hydrate.

[Fig. 4] Differential scanning calorimetry (DSC) pattern of type I crystals.

[Fig. 5] Differential scanning calorimetry (DSC) pattern of type II crystals.

[Fig. 6] Differential scanning calorimetry (DSC) (enlarged) pattern of type II crystals.

[Fig. 7] Differential scanning calorimetry (DSC) pattern of the hydrate.

[Fig. 8] Solubility test results of various crystal forms.

Modes for Carrying Out the Invention

[0015]

The present invention will next be described in detail.

[0016]

Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (hereinafter referred to as compound (1)) are produced through treating an acid salt of compound (1) with a base and neutralizing the treated product with an acid.

[0017]

Examples of the acid salt of compound (1) include inorganic acid salts such as hydrochloride, sulfate, and phosphate; and organic acid salts such as oxalate, malonate, succinate, acetate, and p-toluenesulfonate. Of these, the p-toluenesulfonate is preferred. These acid salts may be produced through any method disclosed in Patent Documents 1 to 3.

[0018]

In a preferred mode of the base treatment of the acid salt of compound (1), a base is dissolved in a solvent, and the acid salt of compound (1) is added to the solution. Examples of the solvent which can solve the acid salt of compound (1) include protic solvents such as water, methanol, ethanol, isopropanol, 1-butyl alcohol, 2-methyl-1-propanol, 2-butanol, 2-methyl-2-propanol, and ethylene glycol. In use, these solvents may be mixed at any ratio, to thereby provide a mixed solvent. Among these solvents, a water-alcohol mixed solvent is preferred, with a water-ethanol (3 : 1 to 10 : 1)

mixed solvent being more preferred.

[0019]

No particular limitation is imposed on the amount, temperature, etc. of the aforementioned solvent, so long as the amount, temperature, etc. allow the acid salt of compound (1) to be dissolved therein.

[0020]

Any base may be used in the base treatment of the acid salt of compound (1), so long as the base can render the solution of the acid salt of compound (1) to be weakly basic. Examples of the base include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, trisodium phosphate, and tripotassium phosphate; and tertiary amines such as triethylamine and diisopropylethylamine. Of these, potassium carbonate and tripotassium phosphate are preferred.

These bases are preferably used in an amount of 2 to 5 mol, more preferably in an amount of 2 to 4 mol, with respect to 1 mol of the acid salt of compound (1).

[0021]

For neutralizing the base-treated solution, an acid such as citric acid, hydrochloric acid, sulfuric acid, or phosphoric acid may be used. Of these, hydrochloric acid is preferred.

[0022]

No particular limitation is imposed on the reaction temperature in neutralization with acid. However, the

temperature is preferably -10°C to 30°C , more preferably 20 to 30°C .

[0023]

Through neutralization with acid, type I crystals of compound (1) are precipitated. Type I crystals of compound (1) may be recovered through drying under reduced pressure with heating.

[0024]

Type II crystals of compound (1) may be produced through recrystallization of compound (1) from an organic solvent. Examples of the recrystallization solvent include methanol, ethanol, 1-propanol, isopropanol, 1-butyl alcohol, 2-methyl-1-propanol, 2-butanol, 2-methyl-2-propanol, tetrahydrofuran, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, ethyl acetate, ether, diisopropyl ether, chloroform, hexane, cyclohexane, heptane, octane, benzene, toluene, and xylene. These solvents may be used singly or in combination of two or more species. The aforementioned recrystallization solvent is preferably an amide-type solvent, more preferably N,N-dimethylformamide. Recrystallization may be carried out by dissolving compound (1) at 60 to 160°C , preferably at 120 to 150°C , and then cooling the solution to 15 to 40°C , preferably to 20 to 30°C .

[0025]

A hydrate of compound (1) may be produced by storing compound (1) under high humidity conditions (e.g., 20 to 30°C , relative humidity (RH): 85% to 97%). The storage time

is at least 10 days.

[0026]

The afore-yielded type I crystals of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 10.1° , 16.0° , 20.4° , 25.7° , and 26.7° . The powder X-ray diffraction spectral pattern is shown in Fig. 1.

The DSC pattern of Fig. 4 has an endothermic peak at about 327°C .

[0027]

The afore-yielded type II crystals of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 9.9° , 16.3° , 18.2° , and 22.4° . The powder X-ray diffraction spectral pattern is shown in Fig. 2.

The DSC pattern of Fig. 5 has an endothermic peak at about 327°C , and that of Fig. 6 has an endothermic peak at about 273°C .

[0028]

The hydrate of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 8.1° , 14.9° , 16.4° , 25.3° , 26.9° , and 27.6° . The powder X-ray diffraction spectral pattern is shown in Fig. 3.

The DSC pattern of Fig. 7 has endothermic peaks at about 107°C and 327°C .

The hydrate of compound (1) is preferably a monohydrate

thereof.

[0029]

In the present invention, the powder X-ray diffraction spectrum refers to a spectrum measured by means of Mini Flex (product of Rigaku Corporation) under the following conditions.

- X-ray source: Cu
- Goniometer: vertical
- Divergence slit: variable
- Scattering slit: 4.2 degree
- Receiving slit: 0.3 mm
- Scanning mode: continuous
- Scanning speed: 2°/min
- Scanning step: 0.02°
- Scanning axis: $\theta/2\theta$
- Scanning range: 3 to 60°

[0030]

Endothermic peaks of DSC refer to those measured by means of DSC 220U (product of Seiko Instruments Inc.) under the following conditions.

- Temperature elevation rate: 10°C/min
- Atmosphere: nitrogen
- Measurement temperature range: 30 to 400°C

[0031]

When the crystals of compound (1) are analyzed by means of the aforementioned apparatuses, crystal forms of compound (1) which have data and spectral patterns similar to one

another are categorized into the same crystal form of the present invention. Also, when the type I crystals of compound (1), the type II crystals of compound (1), or the hydrate of compound (1) of the present invention contains another crystal form in such a small amount as not to be detected through a routine measurement method, it is also categorized into the same crystal form of the present invention.

[0032]

Furthermore, physical property data of powder X-ray diffraction spectra, DSC, etc. might vary slightly due to variation in measurement factors such as crystal growth direction and particle size. Principally, the crystal form of compound (1) of the present invention should be determined by physical property data disclosed in the specification. However, as described above, this principle should not be strict, and slight variation in data of physical properties may be allowed. For example, an angle variation of $\pm 0.5^\circ$ in X-ray diffraction falling within an allowable range should be included in the scope of rights of the present invention.

[0033]

Among crystal forms of compound (1) of the present invention, type I crystals are particularly preferred, from the viewpoints of high water solubility and excellent thermal stability.

[0034]

The crystal forms of compound (1) of the present

invention have excellent water-solubility and thermal stability. Thus, any of the crystal forms can be processed into various pharmaceutical compositions by mixing with a pharmaceutically acceptable carrier. Such a pharmaceutical composition is preferably a solid preparation, particularly preferably a peroral solid preparation.

In production of a peroral solid preparation, crystals of compound (1) are mixed with an optional additive such as a vehicle, a binder, a disintegrator, a lubricant, a colorant, a coating agent, a wetting agent, a sugar coating agent, an antiseptic agent, a preservative, an antioxidant, or a flavoring agent/corrigent. The thus-obtained mixture is formed into preparations in the form of tablet, coated-tablet, granule, powder, capsule, or the like.

The pharmaceutical composition of the present invention is useful as a uric acid level reducing agent or a gout prophylactic/therapeutic agent.

Examples

[0035]

The present invention will next be described in detail by way of Examples and Test Example, which should not be construed as limiting the invention thereto.

[0036]

In the Examples, used are the following abbreviations: ¹H-NMR: proton nuclear magnetic resonance spectrum, DMSO-d₆: deuterated dimethylsulfoxide, Hz: hertz, J: coupling constant, s: singlet, dd: double doublet, and m: multiplet. The "NMR"

refers to a 270 MHz nuclear magnetic resonance spectrum measured by use of TMS (tetramethylsilane) as an internal standard.

[0037]

Example 1: Synthesis of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate

p-Toluenesulfonic acid monohydrate (6.62 g) was added to a water-2-butanol (10 : 1) mixture (55 mL). Subsequently, 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (7.85 g) was added thereto at 80°C, and the resultant mixture was stirred at 80°C for 1 hour. The reaction mixture was cooled to room temperature, and the precipitated crystals were recovered through filtration. The crystals were washed with a water-2-butanol (10 : 1) mixture (40 mL) and dried at 80°C for 10 hours under reduced pressure, to thereby yield 12.6 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate.

¹H-NMR (DMSO-d₆) δ(ppm): 2.29(s, 3H), 7.11(m, 2H), 7.48(dd, 2H, J=6.48, 1.62 Hz), 8.32-8.35(m, 3H), 8.57(dd, 1H, J=1.62, 0.81 Hz), 8.94-8.98(m, 3H)

[0038]

Example 2: Preparation of type I crystals

Potassium carbonate (8.22 g) and 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate (10.0 g) were dissolved in a water-ethanol (9 : 1) mixture (80 mL). 6M hydrochloric acid (15 mL) was added to the solution, and the resultant mixture was stirred

at 20°C for 5 hours. The precipitated crystals were recovered through filtration and washed with water (100 mL). The crystals were dried at 80°C for 23 hours under reduced pressure, to thereby yield 5.78 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile. The thus-obtained crystals exhibited a powder X-ray diffraction pattern shown in Fig. 1 and a DSC profile shown in Fig. 4, indicating that the crystals were type I crystals.

¹H-NMR (DMSO-d₆) δ(ppm): 8.02 (dd, 2H, J=4.59, 1.62 Hz), 8.32(dd, 1H, J=5.13, 1.62 Hz), 8.55(dd, 1H, J=1.62, 1.08 Hz), 8.80(dd, 2H, =4.59, 1.62 Hz), 8.93(dd, 1H, 5.13, 1.08 Hz)

Melting point: 327°C

[0039]

Example 3: Preparation of type II crystals

N,N-dimethylformamide (300 mL) was added to 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (40.0 g), and the mixture was stirred at 150°C for 25 minutes. The thus-obtained solution was cooled to room temperature, and the precipitated crystals were recovered through filtration. The crystals were washed twice with water (200 mL) and dried overnight at 80°C under reduced pressure, to thereby yield 30.4 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile. The thus-obtained crystals exhibited a powde X-ray diffraction pattern shown in Fig. 2 and a DSC profile shown in Fig. 5, indicating that the crystals were type II crystals.

¹H-NMR (DMSO-d₆) δ(ppm): 8.02(dd, 2H, J=4.59, 1.62 Hz),

8.32 (dd, 1H, J=5.13, 1.62 Hz), 8.55 (dd, 1H, J=1.62, 1.08 Hz),
8.80 (dd, 2H, J=4.59, 1.62 Hz), 8.93 (dd, 1H, 5.13, 1.08 Hz)

Melting point: 327°C

[0040]

Example 4: Preparation of hydrate

4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (about 2 g) was stored at 25°C and an RH of 97% for 14 days. The thus-obtained crystals exhibited a powder X-ray diffraction pattern shown in Fig. 3 and a DSC profile shown in Fig. 7, indicating that the crystals were in a hydrate form.

¹H-NMR (DMSO-d₆) δ(ppm): 8.02 (dd, 2H, J=4.59, 1.62 Hz),
8.32 (dd, 1H, J=5.13, 1.62 Hz), 8.55 (dd, 1H, J=1.62, 1.08 Hz),
8.80 (dd, 2H, J=4.59, 1.62 Hz), 8.93 (dd, 1H, 5.13, 1.08 Hz)

Melting point: 327°C

[0041]

Test Example: Solubility test of various crystal forms

The water solubilities of type I crystals, type II crystals, and the hydrate of compound (1) were determined by calculating each sample concentration of its saturated solution determined through measuring absorbance. Fig. 8 shows the results. The water solubility of type I crystals was found to be 6.2 µg/mL, that of type II crystals 4.2 µg/mL, and that of the hydrate 1.9 µg/mL.

As is clear from Fig. 8, type I crystals and type II crystals have excellent water solubility. In particular, the water solubility of type I crystals is remarkably excellent.

[0042]

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

[0043]

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

Claims

1. Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile exhibiting characteristic peaks in powder X-ray diffractometry at diffraction angles 2θ of about 10.1° , 16.0° , 20.4° , 25.7° , and 26.7° .

2. A method for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile as recited in claim 1, the method comprising treating an acid salt of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with a base and subsequently neutralizing the treated product with an acid.

3. A pharmaceutical composition comprising the type I crystals as recited in claim 1, and a pharmaceutically acceptable carrier.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

